Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1062 studies found for:    Open Studies | "Carcinoma, Bronchogenic"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Carcinoma, Bronchogenic"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting SAS in Patients With Bronchial Carcinoma
Conditions: Sleep Apnea Syndrome;   Bronchial Carcinoma
Intervention: Device: sleep apnea screening with ApneaLinkTM
2 Recruiting Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics
Conditions: Tumors;   Carcinoma, Bronchogenic;   Breast Carcinoma;   Cancer of Head and Neck;   Lymphoma, Malignant;   Soft Tissue Neoplasms
Intervention: Drug: 18F-Al-NOTA-PRGD2 PET/CT
3 Not yet recruiting Prevalence of Sleep-disordered Breathing in Patients With a Newly Diagnosed Non Small Cell Lung Cancer
Condition: Bronchial Cancer
Intervention: Device: With and without SDB
4 Unknown  Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy
Condition: Squamous Cell Carcinoma of Bronchus
Intervention: Drug: Gefitinib
5 Unknown  Study to Determine the Efficacy of Bendamustin in Patients With Recurrent Small Cell Lung Cancer (SCLC)
Condition: Recurrent Small Cell Lung Cancer
Intervention: Drug: Bendamustin/Ribomustin
6 Not yet recruiting Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage IB and II Non-small Cell Lung Cancer
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Durvalumab;   Other: Durvalumab plus SBRT
7 Recruiting Comparison of Different Types of Surgery in Treating Patients With Early-stage Non-small Cell Lung Cancer
Conditions: Stage IA Non-small Cell Lung Cancer;   Adenocarcinoma of the Lung;   Squamous Cell Lung Cancer
8 Recruiting Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)
Conditions: Lung Cancer;   Non-small Cell Lung Cancer (NSCLC)
Interventions: Drug: Dasatinib - 1A;   Drug: Afatinib - 1A;   Drug: Dasatinib - 1B;   Drug: Afatinib - 1B
9 Not yet recruiting Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer
Conditions: EGFR Gene Mutation;   Recurrent Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Nimotuzumab;   Biological: Nivolumab
10 Not yet recruiting Combination of Platinum Doublets and Hypofractionated Radiotherapy in NSCLC
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Cisplatin;   Radiation: hypofractionated radiotherapy;   Drug: Pemetrexed;   Drug: Etoposide
11 Not yet recruiting ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC
Conditions: Non-small Cell Lung Cancer Stage III;   Non-Small-Cell Lung Cancer Metastatic;   Adenocarcinoma of Lung;   EGFR Wildtype
Intervention: Genetic: ctDNA analysis
12 Recruiting Apatinib for Extensive Stage Small Cell Lung Cancer After Second/Third Line Chemotherapy.
Condition: Small Cell Lung Cancer
Intervention: Drug: apatinib
13 Not yet recruiting Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)
Condition: Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)
Interventions: Drug: veliparib;   Drug: nivolumab;   Drug: carboplatin;   Drug: pemetrexed;   Drug: paclitaxel
14 Recruiting Bevacizumab in the Treatment of Malignant Pleural Effusions of Non-squamous Non-small Cell Lung Cancer
Condition: Malignant Pleural Effusion
Intervention: Drug: Bevacizumab
15 Not yet recruiting A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
Conditions: Locally Advanced Squamous Non-Small Cell Lung Cancer;   Metastatic Squamous Non-Small Cell Lung Cancer
Interventions: Drug: Necitumumab;   Drug: Gemcitabine;   Drug: Carboplatin
16 Not yet recruiting Anti PD-1 Neo-adjuvant Treatment for NSCLC
Conditions: Non Small Cell Lung Carcinoma;   Stage I;   Stage II
Interventions: Drug: Pembrolizumab 200 mg IV single dose;   Drug: Pembrolizumab 200 mg IV twice interval 21 days;   Drug: Pembrolizumab 200 mg IV Twice interval 21d,surgery after 10d;   Drug: Pembrolizumab 100 mg I.V single dose;   Procedure: Surgical resection of tumor
17 Not yet recruiting 18F-FDG Metabolism Imaging Monitoring Non-small Cell Lung Cancer Curative Effect of Chemotherapy Multicenter Clinical Study
Condition: Non-small-cell Lung Cancer
Intervention: Radiation: 18F-FDG
18 Not yet recruiting A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer
Condition: Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
Interventions: Drug: Durvalumab and Tremelimumab;   Drug: AZD1775 and carboplatin (CBPT)
19 Not yet recruiting Bronchoscopy With Bronchoalveolar Lavage in Identifying Biomarkers of Response to Immune Checkpoint Inhibitors in Patients With Non-small Cell or Small Cell Lung Cancer
Conditions: Non-Small Cell Lung Carcinoma;   Small Cell Lung Carcinoma
Interventions: Procedure: Bronchoscopy with Bronchoalveolar Lavage;   Other: Laboratory Biomarker Analysis
20 Not yet recruiting PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers
Conditions: Neuroendocrine Tumors;   Carcinoma, Small Cell Lung;   Carcinoma, Large Cell Lung;   Merkel Cell Carcinoma;   Pheochromocytoma;   Paraganglioma;   Thyroid Cancer, Medullary;   Neuroendocrine Carcinoma
Intervention: Drug: PEN-221

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years